Amgen Expects Enbrel Prefilled Syringes To "Blunt" Humira Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will launch the new delivery device by the end of November, one month ahead of schedule. Enbrel's growth has been driven by performance in psoriasis, where the product holds the vast majority of market share among biologics.